Data tracker · NHSBSA open data
UK GLP-1 prescribing tracker
NHS prescribers in England issued 393,874 prescription items for GLP-1 medications in June 2025, the latest month the NHS Business Services Authority has published. Over the latest 12 published months that is 3.95m items, up 47.3% on the previous 12 months, at an NHS actual cost of £378.7m. This page rebuilds from the NHSBSA English Prescribing Dataset as new months publish. Prescribing-volume data only: whether any GLP-1 medication is right for a specific person is a decision for their prescriber, and the NHS route comes first.
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-11
Latest month
393,874
prescription items, June 2025
Latest 12 months
3.95m
prescription items
Year on year
+47.3%
latest 12 months vs the previous 12
NHS actual cost
£378.7m
latest 12 months, England primary care
Monthly GLP-1 prescription items, England primary care
July 2023 to June 2025 · Source: NHSBSA English Prescribing Dataset (OGL v3.0)
One bar per published month. An item is one prescribed product dispensed once, not one patient: many people receive one item per month, but items are not a patient headcount. Counts include all licensed uses of these medications (type 2 diabetes and NHS weight management cannot be separated in this dataset).
Month by month
| Month | Items | NHS actual cost |
|---|---|---|
| Jun 2025 | 393,874 | £38.5m |
| May 2025 | 392,432 | £38.3m |
| Apr 2025 | 363,893 | £35.4m |
| Mar 2025 | 350,676 | £34.0m |
| Feb 2025 | 318,011 | £30.7m |
| Jan 2025 | 342,294 | £32.9m |
| Dec 2024 | 322,382 | £30.9m |
| Nov 2024 | 307,592 | £29.4m |
| Oct 2024 | 310,676 | £29.5m |
| Sept 2024 | 281,550 | £26.5m |
| Aug 2024 | 278,795 | £26.1m |
| Jul 2024 | 284,460 | £26.5m |
| Jun 2024 | 244,939 | £22.8m |
| May 2024 | 239,239 | £21.8m |
| Apr 2024 | 231,564 | £20.7m |
| Mar 2024 | 220,587 | £18.3m |
| Feb 2024 | 197,388 | £16.4m |
| Jan 2024 | 202,738 | £17.0m |
| Dec 2023 | 196,173 | £16.3m |
| Nov 2023 | 219,196 | £18.4m |
| Oct 2023 | 219,627 | £18.5m |
| Sept 2023 | 229,131 | £19.4m |
| Aug 2023 | 235,113 | £19.9m |
| Jul 2023 | 244,068 | £20.7m |
June 2025, by chemical substance
INN names as published by the NHS. Data reporting, not a product comparison or recommendation.
| Chemical substance | Items | Share |
|---|---|---|
| Tirzepatide | 215,103 | 54.6% |
| Semaglutide | 127,258 | 32.3% |
| Dulaglutide | 48,416 | 12.3% |
| Exenatide | 2,045 | 0.5% |
| Liraglutide | 1,049 | 0.3% |
| Lixisenatide | 3 | 0.0% |
NHS first
If you are considering a GLP-1 medication for weight management, the NHS route is free at the point of use where you qualify. Start with NHS access to GLP-1 medications and the per-ICB rollout tracker. Your prescriber decides whether any GLP-1 medication is appropriate for you; this page reports prescribing volumes only.
Methodology
- · Source: NHSBSA English Prescribing Dataset (EPD), published monthly by the NHS Business Services Authority under the Open Government Licence v3.0. This is the same open feed that OpenPrescribing.net builds on.
- · What we count: the monthly SUM of prescription items, total quantity, and NHS actual cost across the six GLP-1 receptor agonist chemical substances in English primary-care prescribing (semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, lixisenatide), grouped by BNF chemical substance.
- · Scope: England primary care only (GP and community prescribing). The dataset excludes hospital prescribing and the entire private clinic and online pharmacy market, so true UK GLP-1 use is higher than these figures.
- · Indication caveat: the same chemical substances are licensed for type 2 diabetes and for weight management. Prescription data cannot be split by indication, so these counts cover both.
- · Cost caveat: NHS actual cost is what the NHS pays after discounts and adjustments. It is not a consumer price and says nothing about private-market pricing.
- · Cadence: NHSBSA publishes each month with a lag of several weeks. This page refreshes when we re-run the fetch against the portal; latest published month shown: June 2025. Page data last fetched 2026-06-11.
| Month | Prescription items | NHS actual cost |
|---|---|---|
| Jul 2024 | 284,460 | £26.5m |
| Aug 2024 | 278,795 | £26.1m |
| Sept 2024 | 281,550 | £26.5m |
| Oct 2024 | 310,676 | £29.5m |
| Nov 2024 | 307,592 | £29.4m |
| Dec 2024 | 322,382 | £30.9m |
| Jan 2025 | 342,294 | £32.9m |
| Feb 2025 | 318,011 | £30.7m |
| Mar 2025 | 350,676 | £34.0m |
| Apr 2025 | 363,893 | £35.4m |
| May 2025 | 392,432 | £38.3m |
| Jun 2025 | 393,874 | £38.5m |
Source: NHSBSA English Prescribing Dataset (Open Government Licence v3.0), GLP-1 receptor agonist chemical substances, summed by month
Items are dispensed prescription items, not a patient headcount, and cover all licensed uses (indication cannot be split). England primary care only; hospital and private prescribing excluded. Data last fetched 2026-06-11. Information only, not medical advice.
View as plain-text Markdown
### Monthly GLP-1 prescription items and NHS actual cost, England primary care, latest 12 published months (to June 2025) | Month | Prescription items | NHS actual cost | | --- | --- | --- | | Jul 2024 | 284,460 | £26.5m | | Aug 2024 | 278,795 | £26.1m | | Sept 2024 | 281,550 | £26.5m | | Oct 2024 | 310,676 | £29.5m | | Nov 2024 | 307,592 | £29.4m | | Dec 2024 | 322,382 | £30.9m | | Jan 2025 | 342,294 | £32.9m | | Feb 2025 | 318,011 | £30.7m | | Mar 2025 | 350,676 | £34.0m | | Apr 2025 | 363,893 | £35.4m | | May 2025 | 392,432 | £38.3m | | Jun 2025 | 393,874 | £38.5m | Source: NHSBSA English Prescribing Dataset (Open Government Licence v3.0), GLP-1 receptor agonist chemical substances, summed by month Items are dispensed prescription items, not a patient headcount, and cover all licensed uses (indication cannot be split). England primary care only; hospital and private prescribing excluded. Data last fetched 2026-06-11. Information only, not medical advice.
“Prescription items are a workload measure, not a patient headcount, and this dataset only sees NHS primary care in England. The private weight-management market, which is where most UK weight-loss prescribing of these medications happens today, is invisible here. Treat the trend as a reliable signal of NHS prescribing direction, not as the total number of people in the UK using GLP-1 medications.”
Related: UK peptide and weight-loss medication statistics · GLP-1 cost and supply in the UK · NHS access routes